Castration-resistant prostate cancer

This study looked at a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the drugs could shrink tumors. The study was completed…

This study tested a combination of two drugs—tivozanib and enzalutamide—in men with advanced prostate cancer that had stopped responding to standard hormone therapy. Enzalutamide blocks male hormones that fuel cancer growth, while tivozanib cuts off the tumor's blood supply. The …

This phase II trial tested two drugs—denosumab and enzalutamide—together in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if the combination could slow cancer growth better than enzalutamide alone. Ho…

This phase 2 trial tested two drugs—cabozantinib and abiraterone—together in 54 men with castration-resistant prostate cancer that had spread to bones. The goal was to see if the combination could delay cancer growth. However, the study was stopped early by the sponsor for busine…

This early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…

This study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.

This study aimed to see if a substance in the blood called uPAR can help predict how well men with advanced prostate cancer respond to the drug abiraterone. Only 3 men were enrolled before the study was stopped early. The goal was to find a simple blood test that could guide trea…